Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Fidelio Capital on its acquisition of VetFamily
Mandate

Vinge advises Fidelio Capital on its acquisition of VetFamily

February 20, 2019 M&A

Vinge has advised Fidelio Capital on its acquisition of VetFamily, an alliance for independent veterinary clinics for, inter alia, clinic cooperation and procurement with operations in Sweden, Norway, Denmark, Germany and the Netherlands.

Vinge’s team consisted of, among others, Jonas Bergström, Manne Bergström, Samra Baytar and Fredric Reissmüller (M&A/Corporate), Eva Fredriksson, Mika Jordan, Hedvig Ekdahl and Fredrika Hjelmberg (Commercial Agreements), Karin Virding (Intellectual Property), Johan Karlsson and Sebastian Örndahl (EU, Competition & Regulatory), Sara Strandberg and Sarah Berger (Employment) and Viktoria Owetz (VDR).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026